CRUPI, EMANUELE
 Distribuzione geografica
Continente #
EU - Europa 100
AS - Asia 65
NA - Nord America 61
SA - Sud America 9
AF - Africa 1
Totale 236
Nazione #
RU - Federazione Russa 71
US - Stati Uniti d'America 59
CN - Cina 20
SG - Singapore 20
IT - Italia 10
BR - Brasile 7
VN - Vietnam 7
HK - Hong Kong 5
FR - Francia 4
JP - Giappone 4
PL - Polonia 4
SE - Svezia 4
BD - Bangladesh 3
ES - Italia 2
IN - India 2
AL - Albania 1
AR - Argentina 1
BE - Belgio 1
CA - Canada 1
CO - Colombia 1
DE - Germania 1
GB - Regno Unito 1
IQ - Iraq 1
MX - Messico 1
PK - Pakistan 1
PT - Portogallo 1
SA - Arabia Saudita 1
SN - Senegal 1
UZ - Uzbekistan 1
Totale 236
Città #
San Jose 19
Singapore 11
Moscow 7
Hong Kong 5
Dallas 4
Ashburn 3
Ho Chi Minh City 3
Los Angeles 3
New York 3
Warsaw 3
Bologna 2
Brooklyn 2
Cesano Boscone 2
Milan 2
Orem 2
Shanghai 2
Stockholm 2
Tokyo 2
Allentown 1
Boardman 1
Brussels 1
Cataguases 1
Cleveland 1
Council Bluffs 1
Da Nang 1
Dakar 1
Denver 1
Erbil 1
Faisalabad 1
Grand Junction 1
Grand Rapids 1
Guelph 1
Haining 1
Haiphong 1
Hefei 1
Lauterbourg 1
Lisbon 1
London 1
Louveira 1
Medellín 1
Mexico City 1
Navsari 1
Oldenburg 1
Palmdale 1
Petrolina 1
Phú Thọ 1
Phủ Lý 1
Pune 1
Queen Creek 1
Rio Grande da Serra 1
Riyadh 1
Rome 1
Roubaix 1
Salsipuedes 1
Seattle 1
Sesto San Giovanni 1
São Paulo 1
Tashkent 1
Taubaté 1
Tirana 1
Totale 119
Nome #
Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median follow-up update of PURE-01 trial 99
Neoadjuvant Chemotherapy VI-RADS Scores for Assessing Muscle-invasive Bladder Cancer Response to Neoadjuvant Immunotherapy with Multiparametric MRI 66
Vesical Imaging-Reporting and Data System use predicting the outcome of neoadjuvant pembrolizumab in muscle-invasive bladder cancer 36
First results of NURE-Combo: A phase 2 study of neoadjuvant nivolumab (NIVO) and nab-paclitaxel (ABX) followed by postsurgical adjuvant NIVO in patients (pts) with muscle-invasive bladder cancer (MIBC) 18
Comprehensive genomic profiling (CGP) of clinical T2-4N0M0 muscle-invasive bladder cancer (MIBC) treated with neoadjuvant pembrolizumab or cisplatinbased chemotherapy before radical cystectomy (RC) 8
Utility of fluoro-deoxy-glucose positron emission tomography (FDG-PET) to predict a pelvic lymph node involvement (LNI) in patients (pts) with muscle-invasive bladder cancer (MIBC) enrolled in neoadjuvant therapy trials 6
Distinct Gene Expression Patterns Identify Patients who Relapse After Neoadjuvant Pembrolizumab and Radical Cystectomy in the PURE-01 Study 5
The role of androgen response pathway in association with tumor biology and response to neoadjuvant immune-checkpoint inhibitors (ICI) in muscle-invasive urothelial bladder carcinoma (MIBC) 5
Data from Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial 2
Data from Impact of Molecular Androgen and Estrogen Response Scores on Outcomes Following Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer 2
Impact of Molecular Androgen and Estrogen Response Scores on Outcomes Following Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer 2
Totale 249
Categoria #
all - tutte 948
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 948


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/20234 0 0 0 1 0 1 1 1 0 0 0 0
2023/20245 0 0 2 1 0 1 0 0 0 0 0 1
2024/202515 1 0 1 0 1 3 1 5 0 1 0 2
2025/2026225 6 6 0 10 26 13 11 19 68 30 22 14
Totale 249